- Home
- NSPR vs CRBP Comparison
NSPR vs CRBP Comparison
Compare NSPR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- CRBP
- Stock Information
- Founded
- NSPR 2005
- CRBP 2009
- Country
- NSPR United States
- CRBP United States
- Employees
- NSPR N/A
- CRBP N/A
- Industry
- NSPR Medical/Dental Instruments
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- NSPR Health Care
- CRBP Health Care
- Exchange
- NSPR Nasdaq
- CRBP Nasdaq
- Market Cap
- NSPR 79.7M
- CRBP 73.4M
- IPO Year
- NSPR N/A
- CRBP N/A
- Fundamental
- Price
- NSPR $2.60
- CRBP $6.65
- Analyst Decision
- NSPR Strong Buy
- CRBP Strong Buy
- Analyst Count
- NSPR 2
- CRBP 10
- Target Price
- NSPR $4.75
- CRBP $53.56
- AVG Volume (30 Days)
- NSPR 48.2K
- CRBP 148.0K
- Earning Date
- NSPR 05-09-2025
- CRBP 05-06-2025
- Dividend Yield
- NSPR N/A
- CRBP N/A
- EPS Growth
- NSPR N/A
- CRBP N/A
- EPS
- NSPR N/A
- CRBP N/A
- Revenue
- NSPR $7,009,000.00
- CRBP N/A
- Revenue This Year
- NSPR $28.93
- CRBP N/A
- Revenue Next Year
- NSPR $172.18
- CRBP $150.00
- P/E Ratio
- NSPR N/A
- CRBP N/A
- Revenue Growth
- NSPR 12.96
- CRBP N/A
- 52 Week Low
- NSPR $2.07
- CRBP $4.64
- 52 Week High
- NSPR $3.80
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- NSPR 49.84
- CRBP 48.86
- Support Level
- NSPR $2.40
- CRBP $6.10
- Resistance Level
- NSPR $2.79
- CRBP $8.07
- Average True Range (ATR)
- NSPR 0.16
- CRBP 0.70
- MACD
- NSPR 0.01
- CRBP -0.07
- Stochastic Oscillator
- NSPR 60.42
- CRBP 26.50
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.